{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:53:07Z","timestamp":1784829187759,"version":"3.55.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Carry Life UF is a novel peritoneal dialysis (PD) technology for improved fluid management using steady concentration PD (SCPD). The Carry Life UF treatment starts with a manual peritoneal fill of 1.36% glucose PD fluid, followed by a 5-hour treatment where small amounts of glucose are continuously added to maintain a stable intraperitoneal glucose concentration. A recent in-center clinical study using the Carry Life UF system demonstrated higher ultrafiltration (UF) rates, more efficient use of glucose (increased UF volume\/gram of glucose absorbed), and greater sodium removal with the Carry Life UF treatments compared with a 2.27% glucose continuous ambulatory PD (CAPD) dwell. The aim of this study is to compare efficacy and safety of the Carry Life UF system with a standard CAPD prescription in the home setting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A prospective, multicenter, randomized, crossover study of 19 adult subjects at up to 12 sites in Italy, Sweden and the UK will complete the investigation. End-stage kidney disease patients with a CAPD prescription of 2\u20134 exchanges per day, including at least one 2.27% glucose dwell, will be included. After a Carry Life UF glucose dose determination phase performed in-clinic, subjects will be randomized to start the home treatment part of the study with either the control arm (2.27% glucose CAPD dwell) or the Carry Life UF arm (11 or 15\u00a0g\/h glucose dose), each for four weeks. The primary endpoint is UF volume comparing the control CAPD 2.27% glucose dwell with the Carry Life UF treatment. Secondary endpoints include adverse event rates, peritoneal sodium removal, glucose UF efficiency, and peak dialysate glucose concentration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>This study will evaluate a novel PD technology in the home environment. Challenging aspects include the need to accurately measure UF volumes at home and to support subjects in using a novel technology. The study design considers important parameters for precise UF volume measurements and provides detailed weighing instructions to the study team to ensure consistency between study centers. Research nursing support will be provided for training of subjects and to support endpoint data collection in the subjects\u2019 home. Due to the significant burden associated with the study, subjects will be offered a fair compensation, in accordance with local regulations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>ClinicalTrials.gov Identifier: NCT05874804 Registration date: 18th of April 2023.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12882-025-04095-2","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T21:56:17Z","timestamp":1743717377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A clinical study of efficacy and safety of the Carry Life UF system in continuous ambulatory peritoneal dialysis patients: protocol for a prospective, multicenter, randomized, crossover study"],"prefix":"10.1186","volume":"26","author":[{"given":"Martin","family":"Wilkie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"de Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rgen","family":"Hegbrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Heimb\u00fcrger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"issue":"3","key":"4095_CR1","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/0896860819895364","volume":"40","author":"EA Brown","year":"2020","unstructured":"Brown EA, Blake PG, Boudville N, Davies S, De Arteaga J, Dong J, Finkelstein F, Foo M, Hurst H, Johnson DW, et al. International society for peritoneal dialysis practice recommendations: prescribing high-quality goal-directed peritoneal dialysis. Perit Dial Int. 2020;40(3):244\u201353. https:\/\/doi.org\/10.1177\/0896860819895364","journal-title":"Perit Dial Int"},{"issue":"2","key":"4095_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1053\/j.ajkd.2020.09.010","volume":"77","author":"I Teitelbaum","year":"2021","unstructured":"Teitelbaum I, Glickman J, Neu A, Neumann J, Rivara MB, Shen J, Wallace E, Watnick S, Mehrotra R. KDOQI US commentary on the 2020 ISPD practice recommendations for prescribing high-quality goal-directed peritoneal dialysis. Am J Kidney Dis. 2021;77(2):157\u201371. https:\/\/doi.org\/10.1053\/j.ajkd.2020.09.010","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"4095_CR3","doi-asserted-by":"publisher","first-page":"e53294","DOI":"10.1371\/journal.pone.0053294","volume":"8","author":"Q Guo","year":"2013","unstructured":"Guo Q, Yi C, Li J, Wu X, Yang X, Yu X. Prevalence and risk factors of fluid overload in southern Chinese continuous ambulatory peritoneal dialysis patients. PLoS ONE. 2013;8(1):e53294. https:\/\/doi.org\/10.1371\/journal.pone.0053294","journal-title":"PLoS ONE"},{"issue":"4","key":"4095_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3747\/pdi.2013.00066","volume":"34","author":"BC Kwan","year":"2014","unstructured":"Kwan BC, Szeto CC, Chow KM, Law MC, Cheng MS, Leung CB, Pang WF, Kwong VW, Li PK. Bioimpedance spectroscopy for the detection of fluid overload in Chinese peritoneal dialysis patients. Perit Dial Int. 2014;34(4):409\u201316. https:\/\/doi.org\/10.3747\/pdi.2013.00066","journal-title":"Perit Dial Int"},{"issue":"5","key":"4095_CR5","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1093\/ndt\/gfv013","volume":"30","author":"C Ronco","year":"2015","unstructured":"Ronco C, Verger C, Crepaldi C, Pham J, De Los Rios T, Gauly A, Wabel P, Van Biesen W. Baseline hydration status in incident peritoneal dialysis patients: the initiative of patient outcomes in dialysis (IPOD-PD study). Nephrol Dial Transpl. 2015;30(5):849\u201358. https:\/\/doi.org\/10.1093\/ndt\/gfv013","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"4095_CR6","doi-asserted-by":"publisher","first-page":"e17148","DOI":"10.1371\/journal.pone.0017148","volume":"6","author":"W Van Biesen","year":"2011","unstructured":"Van Biesen W, Williams JD, Covic AC, Fan S, Claes K, Lichodziejewska-Niemierko M, Verger C, Steiger J, Schoder V, Wabel P, et al. Fluid status in peritoneal dialysis patients: the European body composition monitoring (EuroBCM) study cohort. PLoS ONE. 2011;6(2):e17148. https:\/\/doi.org\/10.1371\/journal.pone.0017148","journal-title":"PLoS ONE"},{"issue":"2","key":"4095_CR7","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1046\/j.1523-1755.2001.060002767.x","volume":"60","author":"K Ates","year":"2001","unstructured":"Ates K, Nergizoglu G, Keven K, Sen A, Kutlay S, Ert\u00fcrk S, Duman N, Karatan O, Ertug AE. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int. 2001;60(2):767\u201376. https:\/\/doi.org\/10.1046\/j.1523-1755.2001.060002767.x","journal-title":"Kidney Int"},{"issue":"4","key":"4095_CR8","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1159\/000492148","volume":"46","author":"Y Shu","year":"2018","unstructured":"Shu Y, Liu J, Zeng X, Hong HG, Li Y, Zhong H, Ma L, Fu P. The effect of overhydration on mortality and technique failure among peritoneal dialysis patients: a systematic review and meta-analysis. Blood Purif. 2018;46(4):350\u20138. https:\/\/doi.org\/10.1159\/000492148","journal-title":"Blood Purif"},{"issue":"2","key":"4095_CR9","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1093\/ckj\/sfz175","volume":"14","author":"F Vrtovsnik","year":"2021","unstructured":"Vrtovsnik F, Verger C, Van Biesen W, Fan S, Shin SK, Rodriguez C, Garcia Mendez I, van der Sande FM, De Los Rios T, Ihle K, et al. The impact of volume overload on technique failure in incident peritoneal dialysis patients. Clin Kidney J. 2021;14(2):570\u20137. https:\/\/doi.org\/10.1093\/ckj\/sfz175","journal-title":"Clin Kidney J"},{"issue":"2","key":"4095_CR10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2215\/CJN.0000000000000342","volume":"19","author":"O Heimburger","year":"2023","unstructured":"Heimburger O, Hegbrant J, Martus G, Wilkie M, De Leon C, Carlsson O, Johansson AC. Effects of steady glucose concentration peritoneal dialysis on ultrafiltration volume and sodium removal: a pilot crossover trial. Clin J Am Soc Nephrol. 2023;19(2):224\u201332. https:\/\/doi.org\/10.2215\/CJN.0000000000000342","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"4095_CR11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/d41573-024-00107-2","volume":"23","author":"G Esiason","year":"2024","unstructured":"Esiason G, Pontius A, Gelinas L. Show them the money: a multi-stakeholder perspective on reforming clinical trial participant compensation. Nat Rev Drug Discov. 2024;23(12):881\u20132. https:\/\/doi.org\/10.1038\/d41573-024-00107-2.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"4095_CR12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/089686080602600408","volume":"26","author":"SJ Davies","year":"2006","unstructured":"Davies SJ. Overfill or ultrafiltration? We need to be clear. Perit Dial Int. 2006;26(4):449\u201351.","journal-title":"Perit Dial Int"},{"issue":"6","key":"4095_CR13","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3747\/pdi.2017.00004","volume":"37","author":"V La Milia","year":"2017","unstructured":"La Milia V, Cabiddu G, Virga G, Vizzardi V, Giuliani A, Finato V, Feriani M, Filippini A, Neri L, Lisi L, et al. Peritoneal equilibration test reference values using a 3.86% glucose solution during the first year of peritoneal dialysis: results of a multicenter study of a large patient population. Perit Dial Int. 2017;37(6):633\u20138. https:\/\/doi.org\/10.3747\/pdi.2017.00004","journal-title":"Perit Dial Int"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04095-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04095-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04095-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T21:56:28Z","timestamp":1743717388000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04095-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4095"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04095-2","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by Ethics Committees in Italy (Turin Regional Ethics Committee, 0000138, October 3 2024), Sweden (Ethical Review Authority, 2023-02927-01, May 15 2023), and United Kingdom (North West - Greater Manchester South Research Ethics Committee, 23\/NW\/0138, June 22 2023). The study has been approved by the competent authorities in Italy (Ministry of Health, DGDMF\/I.5.i.m.2\/2024\/2224, August 27 2024), Sweden (Medical Products Agency, 5.1-2023-29063, May 5 2023), and United Kingdom (Medicines and Healthcare products Regulatory Agency, CI\/2023\/0030\/GB, April 17 2023). All subjects will be asked by the principal investigator or a co-investigator at the site to sign an informed consent form prior to entering the study. Consent forms have been modified according to Ethics Committees\/competent authorities in the three countries separately.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The sponsor will maintain appropriate clinical study insurance coverage as required under applicable laws and regulations for the duration of the clinical investigation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Insurances"}},{"value":"This publication will not include any sensitive or traceable data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MW reports consultancy for Triomed AB, speakers honoraria from Baxter, and editorial links with International Society for Peritoneal Dialysis. CDL and OC report employment with Triomed AB. JH serves on the Board of Directors of NorrDia AB, and provides consultancy services to Triomed AB and myjoju Ltd. OH reports research funding from AstraZeneca, Baxter, and Triomed AB; honoraria from AstraZeneca, Baxter Healthcare, Bayer, Ewimed, Fresenius Medical Care, and Vifor for presentations at company-organized courses; speakers bureau for AstraZeneca; and role on Editorial Boards of Blood Purification, Clinical Nephrology, and Peritoneal Dialysis International.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"174"}}